3',5'-diisopropyl-4'-hydroxyacetophenone | 720-19-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3',5'-diisopropyl-4'-hydroxyacetophenone
• 英文别名: 4-acetyl-2,6-diisopropylphenol；1-(4-hydroxy-3,5-diisopropyl-phenyl)ethanone；1-(4-Hydroxy-3,5-diisopropylphenyl)ethanone；1-[4-hydroxy-3,5-di(propan-2-yl)phenyl]ethanone
• CAS: 720-19-4
• 化学式: C₁₄H₂₀O₂
• 分子量: 220.312
• InChiKey: XKIWLMDMULZBTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3',5'-diisopropyl-4'-hydroxyacetophenone 在 溴 、 sodium sulfate 作用下， 以 氯仿 为溶剂， 生成 4-bromoacetyl-2,6-bis(1-methylethyl)phenol
  参考文献：
  名称：

  Pharmaceutically active bicyclic-heterocyclic amines

  摘要：

  具有药用活性的双环杂环胺类化合物（XXX）##STR1##其中W.sub.1为--N.dbd.或--CH.dbd.; W.sub.3为--N.dbd.或--CH.dbd.; W.sub.5为--N.dbd.或--CR.sub.5--，但W.sub.5为--CR.sub.5--当W.sub.1和W.sub.3均为--N.dbd.，这些化合物在治疗轻度和/或中度至重度头部损伤、蛛网膜下腔出血和随后的缺血性中风、哮喘以及减少肺部粘液形成/分泌和其他疾病和损伤中具有药用价值。

  公开号：

  US05502187A1
• 作为产物：
  描述：

  2,6-Diisopropylphenyl acetate 在 三氯化铝 盐酸 作用下， 以 氯仿 为溶剂， 生成 3',5'-diisopropyl-4'-hydroxyacetophenone
  参考文献：
  名称：

  Pharmaceutically active bicyclic-heterocyclic amines

  摘要：

  具有药用活性的双环杂环胺类化合物（XXX）##STR1##其中W.sub.1为--N.dbd.或--CH.dbd.; W.sub.3为--N.dbd.或--CH.dbd.; W.sub.5为--N.dbd.或--CR.sub.5--，但W.sub.5为--CR.sub.5--当W.sub.1和W.sub.3均为--N.dbd.，这些化合物在治疗轻度和/或中度至重度头部损伤、蛛网膜下腔出血和随后的缺血性中风、哮喘以及减少肺部粘液形成/分泌和其他疾病和损伤中具有药用价值。

  公开号：

  US05502187A1

文献信息

• Inhibitors of Acyl-CoA:Cholesterol <i>O</i>-Acyltransferase. 17. Structure−Activity Relationships of Several Series of Compounds Derived from <i>N</i>-Chlorosulfonyl Isocyanate
  作者：Joseph A. Picard、Patrick M. O'Brien、Drago R. Sliskovic、Maureen K. Anderson、Richard F. Bousley、Katherine L. Hamelehle、Brian R. Krause、Richard L. Stanfield

  DOI：10.1021/jm9509455

  日期：1996.3.15

  Several series of acyl-CoA:cholesterol O-acyltransferase inhibitors were prepared by the stepwise addition of nitrogen, oxygen, and sulfur nucleophiles to N-chlorosulfonyl isocyanate. The (aminosulfonyl)ureas 3-44 were the most potent inhibitors in vitro, with several compounds having IC50 values < 1 microM. Although the other series of compounds were not as potent in vitro, many compounds did display

  通过将氮，氧和硫亲核试剂逐步添加到N-氯磺酰基异氰酸酯中，可以制备几种系列的酰基CoA：胆固醇O-酰基转移酶抑制剂。（氨基磺酰基）脲3-44是体外最有效的抑制剂，几种化合物的IC50值<1 microM。尽管其他系列的化合物在体外效果不佳，但许多化合物在以胆固醇喂养的大鼠中确实显示出良好的体内活性。几种氧磺酰基氨基甲酸酯（包括CI-999、115）在慢性体内筛选中显示出出色的降脂活性，表明在预先建立的高胆固醇血症状态下胆固醇显着降低。
• Synthesis and Preliminary Pharmacological Evaluation of Aryl Dithiolethiones with Cyclooxygenase-2-Selective Inhibitory Activity and Hydrogen Sulfide-Releasing Properties
  作者：Shannon D. Zanatta、Bevyn Jarrott、Spencer J. Williams

  DOI：10.1071/ch09517

  日期：——

  A series of 5-aryl-1,2-dithiolethiones and 5-aryl-1,2-dithiole-3-ones were investigated as hydrogen sulfide-releasing anti-inflammatory drugs. Generally, phenolic acetophenones were best protected by methoxymethyl groups and the dithiolethione group installed by treatment with carbon disulfide, hexamethyldisilathiane, and hexachloroethane. However, ether-protected acetophenones could be elaborated to β-keto esters and converted to dithiolethiones by treatment with phosphorus pentasulfide and elemental sulfur. Dethionation of dithiolethiones to 1,2-dithiole-3-ones was accomplished by mercury(ii)-promoted hydrolysis. A preliminary investigation of the dithiolethiones and dithiole-3-ones as inhibitors of cyclooxygenases COX-1 and COX-2 is discussed. Dithiolethiones bearing a 5-(2,6-di-tert-butyl-4-hydroxyphenyl) or 5-(2,6-di-tert-butyl-4-methoxyphenyl) substituent were the most effective inhibitors of COX-2 and displayed excellent selectivity against COX-1, comparable with rofecoxib, a representative coxib. It is shown that uncatalyzed hydrolysis of the thiocarbonyl group to release hydrogen sulfide leads to the corresponding carbonyl compound, and these carbonyl compounds are moderate COX-2 selective inhibitors.

  研究人员对一系列 5-芳基-1,2-二硫代硫酮和 5-芳基-1,2-二硫代硫酮-3-酮作为释放硫化氢的消炎药进行了研究。一般来说，通过二硫化碳、六甲基二硅烷和六氯乙烷的处理，酚类苯乙酮得到甲氧基甲基基团和二硫代乙酮基团的最佳保护。然而，醚保护的苯乙酮可以被加工成 β-酮酯，并通过五硫化二磷和元素硫处理转化成二硫代硫酮。二硫代乙硫醚通过汞（ii）促进的水解作用脱硫成 1,2-二硫代-3-酮。本文讨论了二硫代硫醚和二硫代-3-酮作为环氧化酶 COX-1 和 COX-2 抑制剂的初步研究。具有 5-(2,6-二叔丁基-4-羟基苯基)或 5-(2,6-二叔丁基-4-甲氧基苯基)取代基的二硫代硫iones 是 COX-2 最有效的抑制剂，并且对 COX-1 具有极佳的选择性，可与具有代表性的 Coxib 罗非昔布相媲美。研究表明，硫代羰基在未催化的情况下水解释放出硫化氢会生成相应的羰基化合物，而这些羰基化合物是中度的 COX-2 选择性抑制剂。
• Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
  申请人：Chabrier de Lassauniere Etienne Pierre

  公开号：US20070179153A1

  公开（公告）日：2007-08-02

  A method of treating Parkinson's disease in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount of a compound of the formula wherein the substituents are defined as in the specification

  一种治疗温血动物帕金森病的方法，包括向需要治疗的温血动物施用化合物的有效量，该化合物的化学式如下：其中取代基如规范中定义。
• Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
  申请人：Cuberes Altisen Rosa

  公开号：US20070093469A1

  公开（公告）日：2007-04-26

  The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及通式(I)的取代氮杂环丙烷化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物。
• DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
  申请人：CHABRIER DE LASSAUNIERE Pierre-Etienne

  公开号：US20110172434A1

  公开（公告）日：2011-07-14

  The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R 1 and R 2 are notably independently hydrogen, alkyl or cycloalkyl and Ω is —NR 46 R 47 or —OR 48 , R 46 and R 47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH 2 ) k —COOR 51 , R 51 is notably alkyl or haloalkyl and R 48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.

  本发明涉及通式（I）的噻唑，噁唑，咪唑，异噁唑和异噁唑啉衍生物，其中Het为噻唑，噁唑，咪唑，异噁唑或异噁唑啉，n为0至6的整数，A特别选择自各种可选取代的芳香基团，B特别为氢，烷基或苯基，R1和R2特别独立地为氢，烷基或环烷基，Ω为—NR46R47或—OR48，R46和R47特别独立地为氢，烷基，环烷基或—(CH2)k—COOR51，R51特别为烷基或卤代烷基，R48特别为氢或烷基。这些化合物具有有利的药理学性质，可以在治疗中使用，特别用于治疗神经退行性疾病或疼痛。